TCL Archive FDA approves a new cancer drug, Vidaza, and two sNDAs, without going to ODAC. A date with ODAC may signal a weak case for drug approval, recent approval data indicate. May 28, 2004
TCL Archive “A significant reduction in the NCI IRP AIDS program may be in order, and released funds should … increase the pool available to extramural research.” July 21, 1995
